A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

January 27, 2025

Study Completion Date

April 30, 2026

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Oral Azacitidine

Specified dose on specified days

OTHER

Placebo

Specified dose of specified days

Trial Locations (31)

35801

Local Institution - 0011, Huntsville

1138677

Local Institution - 0032, Bunkyo Ku

1308575

Local Institution - 0029, Sumida Ku

1600023

Local Institution - 0030, Shinjuku-ku

2520375

Local Institution - 0006, Sagamihara-shi

2591193

Local Institution - 0012, Isehara

2778577

Local Institution - 0003, Kashiwa-shi

2968602

Local Institution - 0005, Kamogawa

3710821

Local Institution - 0001, Maebashi

4668560

Local Institution - 0023, Nagoya

5300012

Local Institution - 0026, Osaka

5898511

Local Institution - 0021, Ōsaka-sayama

7000914

Local Institution - 0025, Okayama

7900826

Local Institution - 0010, Matsuyama

8120033

Local Institution - 0027, Fukuoka

8528511

Local Institution - 0008, Nagasaki

9101193

Local Institution - 0020, Yoshida Gun

9208641

Local Institution - 0019, Kanazawa

9808574

Local Institution - 0015, Sendai

453-8511

Local Institution - 0017, Nagoya

470-1192

Local Institution - 0009, Toyoake

0308553

Local Institution - 0022, Aomori

810-8539

Local Institution - 0016, Fukuoka

503-8502

Local Institution - 0014, Ōgaki

0640804

Local Institution - 0004, Sapporo

236-0004

Local Institution - 0013, Yokohama

329-0498

Local Institution - 0031, Shimotsuke

141-8625

Local Institution - 0002, Shinagawa

810-8563

Local Institution - 0018, Fukuoka

330-8503

Local Institution - 0028, Saitama

990-9585

Local Institution - 0007, Yamagata

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05197426 - A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission | Biotech Hunter | Biotech Hunter